spacer
home > ebr > spring 2019 > a new class of innovation
PUBLICATIONS
European Biopharmaceutical Review

A New Class of Innovation

EBR: What promise do advanced therapy medicinal products (ATMPs) offer in terms of treatment?

ATMPs are a rapidly growing, diverse variety of technologies covering a various range of therapeutic areas. The technologies include:

• Autologous cell therapies: Cells removed from a patient, processed in some way, and returned to the same patient
• Allogeneic cell therapies: Cells capable of being banked and can be administered to multiple patients after processing
• Ex vivo gene therapies: Autologous or allogeneic cell therapies which are genetically modified as part of the Good Manufacturing Practice process (to correct a faulty gene or target the cell in a predetermined way to, for example, attack a tumour) prior to being returned to the patient
• In vivo gene therapies: Direct injection of a viral or nonviral delivery system which will correct one or more faulty genes in the body

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Angela Osborne is Managing Director at eXmoor Pharma Concepts, which she founded in 2004. Angela has a BSc and PhD in biochemical engineering from University College London, UK, and over 30 years’ experience in biopharmaceutical and cell and gene therapy businesses, processes, and facilities. Her previous roles include Senior Vice President of Pharmaceuticals at Aker Kvaerner and Group Leader of Process Engineering at British Biotech. eXmoor is now a globally recognised biopharmaceutical and cell and gene therapy manufacturing consultancy that has completed more than 300 projects across 12 countries. Angela is also a member of the BioIndustry's Association Cell Therapy Industry Group Advisory Committee and the Manufacturing Advisory Committee as well as the co-founder of the ATMP Manufacturing Community.
spacer
Dr Angela Osborne
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPhI MEA expert:growing domestic manufacturing is creating new opportunities for international Pharma in the Middle East

Abu Dhabi, 5th August 2019: CPhI Middle East expert Emad Shabbir, Director at EMAD Trade House, states favorable conditions and legislative regulations in Saudi Arabia are resulting in a boom of manufacturers and CMOs partnerships with international pharma companies. With the strategic cooperation between regional generic companies and multinational pharma companies, driving increased local production.
More info >>

White Papers

The Power of Execution in Clinical Research

Medpace

Medpace, long known for its excellence in conducting Phase I-IV studies on a global platform, is particularly noted for its therapeutic excellence. When that expertise is combined with operational precision, the results are nothing short of stellar. The Medpace full-service outsourcing approach – combined with therapeutic expertise, regulatory know how, and global presence – delivers clinical studies with an industry recognized track record.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement